Jump Financial LLC Has $20.93 Million Stock Holdings in Axon Enterprise, Inc $AXON

Key Points

• Jump Financial LLC increased its stake in Axon Enterprise, Inc by 8.6%, owning approximately 39,797 shares valued at $20.93 million at the end of the reporting period.
• Axon's revenue rose by 32.6% year-over-year, reporting $668.54 million for the quarter, and EPS of $2.12 surpassed analyst expectations.
• Investment firms are optimistic about Axon, with multiple analysts raising their price targets, resulting in an average target of $837.69 and a consensus rating of "Moderate Buy".

Jump Financial LLC grew its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 8.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,797 shares of the biotechnology company's stock after buying an additional 3,151 shares during the period. Jump Financial LLC owned 0.05% of Axon Enterprise worth $20,931,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in shares of Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after purchasing an additional 763,431 shares in the last quarter. Jennison Associates LLC grew its position in Axon Enterprise by 23,203.7% during the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company's stock worth $322,961,000 after buying an additional 611,418 shares in the last quarter. Nuveen LLC bought a new stake in Axon Enterprise during the first quarter worth about $264,796,000. Westfield Capital Management Co. LP lifted its stake in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock valued at $487,977,000 after acquiring an additional 212,931 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock valued at $4,540,005,000 after acquiring an additional 185,571 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Activity

In other news, President Joshua Isner sold 15,919 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the transaction, the president owned 238,379 shares of the company's stock, valued at approximately $177,892,712.54. This trade represents a 6.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Jennifer H. Mak sold 75 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $771.81, for a total transaction of $57,885.75. Following the sale, the chief accounting officer directly owned 15,240 shares of the company's stock, valued at approximately $11,762,384.40. The trade was a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 43,790 shares of company stock valued at $33,654,451 in the last 90 days. Insiders own 4.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on AXON shares. Craig Hallum upgraded Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target on the stock in a research note on Tuesday, August 5th. Barclays increased their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the stock an "overweight" rating in a research note on Friday, July 11th. Wolfe Research initiated coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They issued an "outperform" rating for the company. Finally, JMP Securities lifted their price target on shares of Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 22nd. Thirteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus price target of $837.69.

Axon Enterprise Stock Performance

AXON traded up $21.48 on Thursday, reaching $791.16. The company had a trading volume of 281,068 shares, compared to its average volume of 696,953. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $62.11 billion, a PE ratio of 195.35, a P/E/G ratio of 28.22 and a beta of 1.36. Axon Enterprise, Inc has a 1 year low of $346.71 and a 1 year high of $885.91. The stock has a 50-day moving average price of $772.52 and a 200-day moving average price of $675.87.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. During the same period in the previous year, the business posted $1.20 earnings per share. The business's revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.